Qsymia
Phentermine/Topiramate ER
Qsymia is a once-daily oral combination of phentermine (a sympathomimetic appetite suppressant) and topiramate ER (an anticonvulsant with weight loss effects). FDA-approved for chronic weight management, it reduces appetite, increases satiety, and alters taste perception, making calorie reduction more sustainable. Qsymia has been shown to produce meaningful weight loss when paired with diet and exercise, particularly in patients who do not tolerate or have access to newer GLP-1–based therapies. It offers a non-injectable, cost-effective alternative, though it requires monitoring for mood changes, cognitive effects, and teratogenic risks in women of childbearing potential, necessitating strict contraceptive use during treatment.
- Manufacturer: Vivus
- Primary Use: Chronic Weight Management
- Form: Oral
Common Side Effects
The most common side effects of Qsymia may include:
- Paresthesia
- Dry Mouth
- Constipation
- Insomnia
- Dysgeusia
This is not a complete list. Always consult with your healthcare provider about potential side effects.
Medical Disclaimer
The information provided for Qsymia is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Read our full disclaimer.